- Home
- ENLT vs AZTA Comparison
ENLT vs AZTA Comparison
Compare ENLT & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- AZTA
- Stock Information
- Founded
- ENLT 2008
- AZTA 1978
- Country
- ENLT Israel
- AZTA United States
- Employees
- ENLT N/A
- AZTA N/A
- Industry
- ENLT
- AZTA Industrial Machinery/Components
- Sector
- ENLT
- AZTA Technology
- Exchange
- ENLT Nasdaq
- AZTA Nasdaq
- Market Cap
- ENLT 2.0B
- AZTA 1.8B
- IPO Year
- ENLT 2023
- AZTA 1995
- Fundamental
- Price
- ENLT $19.50
- AZTA $26.72
- Analyst Decision
- ENLT Buy
- AZTA Buy
- Analyst Count
- ENLT 3
- AZTA 3
- Target Price
- ENLT $19.67
- AZTA $50.67
- AVG Volume (30 Days)
- ENLT 28.0K
- AZTA 1.1M
- Earning Date
- ENLT 05-06-2025
- AZTA 05-07-2025
- Dividend Yield
- ENLT N/A
- AZTA N/A
- EPS Growth
- ENLT 90.47
- AZTA N/A
- EPS
- ENLT 0.98
- AZTA N/A
- Revenue
- ENLT $397,296,000.00
- AZTA $669,171,000.00
- Revenue This Year
- ENLT $355.90
- AZTA N/A
- Revenue Next Year
- ENLT $42.83
- AZTA $4.89
- P/E Ratio
- ENLT $19.18
- AZTA N/A
- Revenue Growth
- ENLT 44.42
- AZTA 8.56
- 52 Week Low
- ENLT $14.01
- AZTA $23.91
- 52 Week High
- ENLT $20.19
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- ENLT 62.94
- AZTA 44.87
- Support Level
- ENLT $16.87
- AZTA $26.96
- Resistance Level
- ENLT $20.19
- AZTA $28.32
- Average True Range (ATR)
- ENLT 0.63
- AZTA 1.10
- MACD
- ENLT 0.05
- AZTA 0.19
- Stochastic Oscillator
- ENLT 79.26
- AZTA 15.71
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.